Women who have completed their childbearing, particularly those who have

failed medical management or endometrial ABT-888 solubility dmso ablation, are candidates for hysterectomy. Because menorrhagia is often the primary symptom that women with bleeding disorders experience, hysterectomy does offer the possibility for significant improvement in quality of life and is a safer procedure than it was decades ago. Thirty-six years ago when Silwer et al. published the results of a comparison of the complications of hysterectomy in 18 women with VWD vs. 50 controls, 50% of the women with VWD received transfusion, but so did 30% of the controls [17]. In a recent study of United States hospital discharge data, only 7% of women with VWD received transfusions compared to 2% of controls [41]. Furthermore, in the last 20 years, the availability of recombinant or plasma-derived/virally inactivated clotting factor concentrates has reduced the chance of viral transmission with factor replacement. There are few data on management

of acute, severe menorrhagia, particularly in the adolescent or woman with a bleeding disorder. In November, 2009, a consensus conference sponsored by CSL Behring Selleckchem Bortezomib was convened specifically to address this issue. A full report will be published in the future, but there was consensus that balloon tamponade, hormonal therapy (oestrogen) and antifibrinolytic treatment should be instituted while replacing clotting factor or platelets as indicated. It is recognized that normal pregnancy is accompanied by increased concentrations of various clotting factors. Despite improved haemostasis, however, women with bleeding disorders often do not achieve the same levels of clotting factors as other women and, therefore, are at an increased risk of bleeding complications with pregnancy. In the last 20 years, there have been several case reports and case series documenting the profoundly increased risk of miscarriage and placental

abruption resulting in foetal loss or premature delivery in women with deficiency of fibrinogen [42–51], or factor XIII [52–55] but whether there is an increased risk of miscarriage in women with other bleeding disorders is not clear [18]. Clotting factor replacement is used to reduce the risk of miscarriage, foetal loss and premature 上海皓元医药股份有限公司 delivery in women with deficiency of fibrinogen [43–45,47–51] and factor XIII [52–55], but whether any therapy is necessary or available to prevent miscarriage or foetal loss in women with other bleeding disorders has not been reported. Despite the primary role of uterine contractility in controlling postpartum blood loss, women with bleeding disorders are at an increased risk of postpartum haemorrhage. There are multiple case series documenting the incidence of postpartum haemorrhage in women with bleeding disorders [18] and four case-control studies comparing women with VWD and controls.

6-2.44; and tertile 3, AADRI-C >2.44) were 69%, 54%, and 39%, respectively (P < = 0.001) (Fig. 1). The 1-year, 3-year, and 5-year predicted graft survival for AADRI-C tertile 1 were 91%, 77%, and 68%; for AADRI-C tertile 2 were 86%, 67%, and 55%; and for AADRI-C tertile 3 were 79%, 53%, and 39%, respectively. Predicted graft survival for tertiles of AADRI-C and DRI are shown (Supporting Fig. 2).

Examples of combinations of donor age, donor race, and CIT and the corresponding predicted AADRI-C survival rates are shown in Table 5. These examples reflect the strong favorable influence of AA donor race on HCV-positive AA recipient graft outcomes. For example, an HCV-positive AA receiving a 59-year-old graft from an AA with 8 hours CIT would be predicted to have ∼15% higher graft survival than receiving a similar graft donated by a non-AA or comparable graft survival to receiving a <40-year-old graft from a non-AA Vismodegib order donor with 8 hours of CIT. Compared to the original DRI, XL184 AADRI-C better predicted risk of graft failure in AA HCV-positive recipients in both the development (C-index 0.56 and 0.60, respectively) and validation (C-index 0.51 and 0.55, respectively) datasets. Furthermore, estimated 1-year risk of graft loss

calculated by AADRI-C correctly reclassified 19% of patients (NRI P < 0.001) in the development dataset and 27% of patients (NRI P = 0.04) in the validation dataset. In our disease-specific and race-specific assessment of donor quality and its association with graft failure in HCV-infected AA transplant recipients, the only donor factors of importance were age, race, and CIT. The AADRI-C classifies

risk of graft loss among AA recipients more accurately than the original DRI. Donor age—as in the original DRI—remains the dominant predictor of graft outcome in HCV-positive recipients in the AADRI-C model. However, for the first time we identify a potential age effect modifier, namely, donor AA race. We found that receipt of an AA donor liver attenuated the negative effect of increasing donor age on graft survival. Specifically, compared to AA recipients with donors under the age of 40 years, AA recipients of livers from AA donors had no statistically significant MCE公司 decline in graft survival until the donor age was 60 years or greater. This is a particularly important finding given that the original DRI found that, among all transplant recipients, graft outcomes were inferior with use of livers from AA donors.[10] The DRI remains a landmark innovation for discussing donor risk in LT. However, limitations in the DRI noted since its original presentation may hamper its current utility. For instance, DRI includes a great deal of pre-MELD era data that may not reflect post-MELD trends in donor quality. Also, over time, donors have become older and more obese, while recipients have become more ill on average.

6-2.44; and tertile 3, AADRI-C >2.44) were 69%, 54%, and 39%, respectively (P < = 0.001) (Fig. 1). The 1-year, 3-year, and 5-year predicted graft survival for AADRI-C tertile 1 were 91%, 77%, and 68%; for AADRI-C tertile 2 were 86%, 67%, and 55%; and for AADRI-C tertile 3 were 79%, 53%, and 39%, respectively. Predicted graft survival for tertiles of AADRI-C and DRI are shown (Supporting Fig. 2).

Examples of combinations of donor age, donor race, and CIT and the corresponding predicted AADRI-C survival rates are shown in Table 5. These examples reflect the strong favorable influence of AA donor race on HCV-positive AA recipient graft outcomes. For example, an HCV-positive AA receiving a 59-year-old graft from an AA with 8 hours CIT would be predicted to have ∼15% higher graft survival than receiving a similar graft donated by a non-AA or comparable graft survival to receiving a <40-year-old graft from a non-AA NU7441 research buy donor with 8 hours of CIT. Compared to the original DRI, Erlotinib cell line AADRI-C better predicted risk of graft failure in AA HCV-positive recipients in both the development (C-index 0.56 and 0.60, respectively) and validation (C-index 0.51 and 0.55, respectively) datasets. Furthermore, estimated 1-year risk of graft loss

calculated by AADRI-C correctly reclassified 19% of patients (NRI P < 0.001) in the development dataset and 27% of patients (NRI P = 0.04) in the validation dataset. In our disease-specific and race-specific assessment of donor quality and its association with graft failure in HCV-infected AA transplant recipients, the only donor factors of importance were age, race, and CIT. The AADRI-C classifies

risk of graft loss among AA recipients more accurately than the original DRI. Donor age—as in the original DRI—remains the dominant predictor of graft outcome in HCV-positive recipients in the AADRI-C model. However, for the first time we identify a potential age effect modifier, namely, donor AA race. We found that receipt of an AA donor liver attenuated the negative effect of increasing donor age on graft survival. Specifically, compared to AA recipients with donors under the age of 40 years, AA recipients of livers from AA donors had no statistically significant MCE decline in graft survival until the donor age was 60 years or greater. This is a particularly important finding given that the original DRI found that, among all transplant recipients, graft outcomes were inferior with use of livers from AA donors.[10] The DRI remains a landmark innovation for discussing donor risk in LT. However, limitations in the DRI noted since its original presentation may hamper its current utility. For instance, DRI includes a great deal of pre-MELD era data that may not reflect post-MELD trends in donor quality. Also, over time, donors have become older and more obese, while recipients have become more ill on average.

However, a 30-day treatment of chimeric mice with erlotinib, a small molecule that specifically inhibits EGF-receptor

activity, did not prevent but only delayed the kinetics of infection. In conclusion, we show here that the human monoclonal antibody mAb16-71 can efficiently block in vitro and in vivo infection by multiple HCV genotypes. In addition, we demonstrate that blockade of SR-BI after infection can prevent rapid virus spread through the liver parenchyma, presumably by interfering with SR-BI-dependent cell-free as well as direct cell-to-cell HCV transmission. Therefore, targeting SR-BI may represent a superior strategy for anti-HCV immunotherapy to prevent the emergence of escape mutants and virus rebound during or following antiviral therapy, and to prevent allograft www.selleckchem.com/products/NVP-AUY922.html infection in chronically infected HCV patients undergoing orthotopic

liver transplantation. We thank Dr. Veronique Stove and Yvonne Geybels for the analysis of mouse plasma and Dr. Robert H. Purcell (NIH) and Dr. Jens Bukh (NIH; CO-HEP, Copenhagen) for providing plasma from acutely infected chimpanzees. Additional Supporting Information may be found in the online version of this article. “
“During bile duct ligation (BDL), the growth of large cholangiocytes is regulated by the cyclic adenosine monophosphate (cAMP)/extracellular signal-regulated kinase 1/2 (ERK1/2) pathway and is closely associated with increased secretin receptor (SR) expression. Although it has been suggested that SR modulates cholangiocyte growth, direct evidence for secretin-dependent proliferation is lacking. SR wild-type (WT) (SR+/+) or SR knockout (SR−/−) mice underwent sham surgery or BDL for 3 or 7 days. We evaluated Apoptosis Compound Library SR expression, cholangiocyte proliferation, and apoptosis in liver sections and proliferating cell nuclear antigen (PCNA) protein expression and ERK1/2 phosphorylation in purified large cholangiocytes from WT and SR−/− BDL mice. Normal WT mice were treated with secretin (2.5 nmoles/kg/day by way of osmotic minipumps for 1 week), and biliary mass was 上海皓元 evaluated. Small and large cholangiocytes were

used to evaluate the in vitro effect of secretin (100 nM) on proliferation, protein kinase A (PKA) activity, and ERK1/2 phosphorylation. SR expression was also stably knocked down by short hairpin RNA, and basal and secretin-stimulated cAMP levels (a functional index of biliary growth) and proliferation were determined. SR was expressed by large cholangiocytes. Knockout of SR significantly decreased large cholangiocyte growth induced by BDL, which was associated with enhanced apoptosis. PCNA expression and ERK1/2 phosphorylation were decreased in large cholangiocytes from SR−/− BDL compared with WT BDL mice. In vivo administration of secretin to normal WT mice increased ductal mass. In vitro, secretin increased proliferation, PKA activity, and ERK1/2 phosphorylation of large cholangiocytes that was blocked by PKA and mitogen-activated protein kinase kinase inhibitors.

Given the exploratory fashion, a per-protocol analysis was deemed appropriate and conducted to further minimize Type II error. A mixed-design analysis of variance (ANOVA) with a within-subjects factor of month of treatment (baseline, month 1, month 2, and month 3) and a between-subject factor of treatment group (SumaRT/NAP, naproxen) was used to analyze data for statistical significance. Mean comparison of pairs was conducted by post-hoc analyses. Data were analyzed

from the per-protocol population. Fifty-six subjects were screened for this study, satisfying the proposed sample size of 40 subjects. The study population consisted of 28 subjects who randomized per protocol; 6 males and 22 females with a mean age of 40.9 years and with a diagnosis of ICHD-II chronic migraine; 28 were Caucasian. During month 1 – preventative treatment phase, 20 subjects completed month 1 of the Ruxolitinib manufacturer study: 15 in group A and 5 in group B. Two subjects withdrew during month 1 (one from group A and one from group B) both because of lack of efficacy. Selumetinib mw An additional 6 subjects in group B withdrew at visit 3 (the preventative phase of the study); 4 due to lack of efficacy, 1 lost to follow-up, and 1 due to lack of compliance. During months 2 and 3 – acute treatment phase, 20 subjects

completed both months of the study; 15 of 16 in group A (SumaRT/Nap) and 5 of 12 in group B (naproxen sodium). In both arms of the study, there was a reduction in headache days from baseline to month 1, 2, and 3. This reduction reached statistical significance for group A (SumaRT/Nap) only at month 1 for the per-protocol population. Statistical significance was observed for group B (naproxen sodium) for all 3 months compared to baseline and between

groups, naproxen sodium was statistically superior to SumaRT/Nap for all 3 months for the per-protocol population (Fig. 1 —, Table 1). The duration of migraine from treatment to pain-free decreased in both treatment groups. In group B, there was a greater decrease in duration of migraine compared to those in group A (Fig. 2 —, Table 2). In group A, 3 of 15 subjects experienced a greater than 50% reduction in migraine headache 上海皓元 days during months 1 and 3. A single subject in group A had a greater than 50% reduction in headaches/month for 2 of the 3 months of active study and none for all 3 months of the study. In group B, 4 out of 5 subjects experienced a greater than 50% reduction in migraine headaches days during months 1 and 3. During month 2, 3 out of 5 had a greater than 50% reduction in migraine headache days. Three of the 5 subjects had a greater than 50% reduction in migraine headache days for all 3 months of the active phases of the study (Fig. 3 —).

Given the exploratory fashion, a per-protocol analysis was deemed appropriate and conducted to further minimize Type II error. A mixed-design analysis of variance (ANOVA) with a within-subjects factor of month of treatment (baseline, month 1, month 2, and month 3) and a between-subject factor of treatment group (SumaRT/NAP, naproxen) was used to analyze data for statistical significance. Mean comparison of pairs was conducted by post-hoc analyses. Data were analyzed

from the per-protocol population. Fifty-six subjects were screened for this study, satisfying the proposed sample size of 40 subjects. The study population consisted of 28 subjects who randomized per protocol; 6 males and 22 females with a mean age of 40.9 years and with a diagnosis of ICHD-II chronic migraine; 28 were Caucasian. During month 1 – preventative treatment phase, 20 subjects completed month 1 of the XAV-939 concentration study: 15 in group A and 5 in group B. Two subjects withdrew during month 1 (one from group A and one from group B) both because of lack of efficacy. GSK126 An additional 6 subjects in group B withdrew at visit 3 (the preventative phase of the study); 4 due to lack of efficacy, 1 lost to follow-up, and 1 due to lack of compliance. During months 2 and 3 – acute treatment phase, 20 subjects

completed both months of the study; 15 of 16 in group A (SumaRT/Nap) and 5 of 12 in group B (naproxen sodium). In both arms of the study, there was a reduction in headache days from baseline to month 1, 2, and 3. This reduction reached statistical significance for group A (SumaRT/Nap) only at month 1 for the per-protocol population. Statistical significance was observed for group B (naproxen sodium) for all 3 months compared to baseline and between

groups, naproxen sodium was statistically superior to SumaRT/Nap for all 3 months for the per-protocol population (Fig. 1 —, Table 1). The duration of migraine from treatment to pain-free decreased in both treatment groups. In group B, there was a greater decrease in duration of migraine compared to those in group A (Fig. 2 —, Table 2). In group A, 3 of 15 subjects experienced a greater than 50% reduction in migraine headache MCE公司 days during months 1 and 3. A single subject in group A had a greater than 50% reduction in headaches/month for 2 of the 3 months of active study and none for all 3 months of the study. In group B, 4 out of 5 subjects experienced a greater than 50% reduction in migraine headaches days during months 1 and 3. During month 2, 3 out of 5 had a greater than 50% reduction in migraine headache days. Three of the 5 subjects had a greater than 50% reduction in migraine headache days for all 3 months of the active phases of the study (Fig. 3 —).

Answers to these questions may provide insight into basic mechanisms of cholestasis and lead to novel therapeutic approaches for this condition. We thank Kathy Harry and Albert Mennone for help with hepatocyte isolations and Carol Soroka for help with estradiol and LPS Selleckchem BMS-777607 treatments. We thank Alan Hofmann for providing cholylglycylamido-fluorescein. “
“Peginterferon (PEG IFN) and ribavirin combination therapy is a curative treatment for chronic hepatitis C virus (HCV) infection, and virological response to IFN therapy has been strongly associated with genetic variation

in IL28B single nucleotide polymorphisms (SNP). Recently, miRNA122 (miR-122), which is the most abundant miRNA in the liver, has been reported to be important for the replication of HCV RNA. Therefore, we investigated the correlation of miR-122 expression with virological response to IFN and other clinical HM781-36B molecular weight data. A total of 51 patients with HCV infection who were treated with IFN therapy at Nagasaki University Hospital from 2006 to 2011 were included in this study. We investigated the correlation of miR-122 expression in liver biopsy specimens with virological response to IFN therapy and other predictors

of response, including IL28 SNP. miR-122 expression did not correlate with IL28 SNP. However, a significant difference was observed in miR-122 expression between patients who showed a sustained virological response (SVR) and those who did not (P < 0.05). Multivariate analysis indicated that miR-122 is an independent predictor of SVR. miR-122 expression could be a marker for predicting the outcome of IFN therapy. Therapies targeting miR-122 may MCE公司 have positive effects not only by directly inhibiting viral propagation but also by ameliorating cholesterol and lipid abnormalities. “
“We read with interest the article by Feldstein et al.,1 in which they validated the use of cytokeratin-18 (CK-18) fragment serum levels as a noninvasive biomarker for the diagnosis of

nonalcoholic steatohepatitis (NASH) in a large cohort of adults with biopsy-proven nonalcoholic fatty liver disease (NAFLD). According to their conclusions, this test can be reliably used to diagnose NASH among patients with suspected NAFLD in clinical practice. This is an important study, because it confirms the significant associations between high CK-18 fragment levels and NASH reported in previous smaller studies in other cohorts of adults2, 3 or even children with NAFLD.4 However, we would like to draw your attention to two issues: terminology and predictability. The “Keratin Nomenclature Committee” recently established the new consensus nomenclature for mammalian keratin genes and proteins,5 which is based on and extends the first comprehensive keratin nomenclature developed back in 1982.

While the diatoxanthin (Dt) content of whole cells was enhanced under HL, no decrease was observed under lowered iron supply, ruling out the possibility that the

decreased amounts in FCPa were due to a hampered diadinoxanthin de-epoxidase activity under these conditions. Thus, diatoxanthin not bound to FCPa has to be responsible for protection under the slight reduction in iron supply used here. “
“The applicability of six fluorescent probes (four esterase probes: acetoxymethyl ester of Calcein [Calcein-AM], 5-chloromethylfluorescein diacetate [CMFDA], fluorescein diacetate [FDA], and 2′,7′-dichlorofluorescein diacetate [H2DCFDA]; and two membrane probes: bis-(1,3-dibutylbarbituric acid) trimethine oxonol [DiBAC4(3)] and SYTOX-Green) as vitality stains was tested on live and killed cells of 40 phytoplankton strains in exponential and stationary Ceritinib concentration growth phases, belonging to 12 classes and consisting learn more of four cold-water, 26 temperate, and four warm-water species. The combined live/dead ratios of all six probes indicated significant differences between the 12 plankton classes (P < 0.01) and between individual

species (P < 0.05). No specific differences were observed among strains of one species, among species or strains from different origin, nor between cells in exponential and stationary growth phase except for FDA. FDA showed a significant (P < 0.05) drop of <20% in fluorescence intensity in stationary cells. Of the four esterase probes, the live/dead ratios of FDA and CMFDA were not significantly different from each other, and both performed better than Calcein-AM and H2DCFDA (P < 0.001). Of the two membrane probes, DIBAC4(3) stained rhodophytes and euglenophytes much better than 上海皓元 SYTOX-Green. The 13 algal strains best stainable (high live/dead ratios) among all six probes belonged to nine genera from six classes of phytoplankton. In conclusion, FDA, CMFDA, DIBAC4(3), and SYTOX-Green represent a wide choice

of vitality probes in the study of phytoplankton ecology, applicable in many species from different algal classes, originating from different regions and at different stages of growth. “
“Common methods for assaying acyl-CoA:diacylglycerol acyltransferase (DGAT) enzymatic activity rely upon radiolabeled substrates or product assay. We developed a novel assay that directly quantifies endogenous DGAT activity through the use of a fluorescently labeled substrate. We performed this assay with microsomal protein, 2-(6-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)hexanoyl-1-hexadecanoyl-sn-glycero-3-diacylglycerol (NBD-DAG), and oleoyl-CoA substrates. DGAT activity was analyzed in three species of algae as well as rat liver. The protocol proved to be sensitive and reliable. This assay may be used to facilitate research in the areas of biodiesel, oilseed crops, and triacylglycerol-related human pathologies.

While the diatoxanthin (Dt) content of whole cells was enhanced under HL, no decrease was observed under lowered iron supply, ruling out the possibility that the

decreased amounts in FCPa were due to a hampered diadinoxanthin de-epoxidase activity under these conditions. Thus, diatoxanthin not bound to FCPa has to be responsible for protection under the slight reduction in iron supply used here. “
“The applicability of six fluorescent probes (four esterase probes: acetoxymethyl ester of Calcein [Calcein-AM], 5-chloromethylfluorescein diacetate [CMFDA], fluorescein diacetate [FDA], and 2′,7′-dichlorofluorescein diacetate [H2DCFDA]; and two membrane probes: bis-(1,3-dibutylbarbituric acid) trimethine oxonol [DiBAC4(3)] and SYTOX-Green) as vitality stains was tested on live and killed cells of 40 phytoplankton strains in exponential and stationary Smoothened Agonist supplier growth phases, belonging to 12 classes and consisting selleck compound of four cold-water, 26 temperate, and four warm-water species. The combined live/dead ratios of all six probes indicated significant differences between the 12 plankton classes (P < 0.01) and between individual

species (P < 0.05). No specific differences were observed among strains of one species, among species or strains from different origin, nor between cells in exponential and stationary growth phase except for FDA. FDA showed a significant (P < 0.05) drop of <20% in fluorescence intensity in stationary cells. Of the four esterase probes, the live/dead ratios of FDA and CMFDA were not significantly different from each other, and both performed better than Calcein-AM and H2DCFDA (P < 0.001). Of the two membrane probes, DIBAC4(3) stained rhodophytes and euglenophytes much better than 上海皓元医药股份有限公司 SYTOX-Green. The 13 algal strains best stainable (high live/dead ratios) among all six probes belonged to nine genera from six classes of phytoplankton. In conclusion, FDA, CMFDA, DIBAC4(3), and SYTOX-Green represent a wide choice

of vitality probes in the study of phytoplankton ecology, applicable in many species from different algal classes, originating from different regions and at different stages of growth. “
“Common methods for assaying acyl-CoA:diacylglycerol acyltransferase (DGAT) enzymatic activity rely upon radiolabeled substrates or product assay. We developed a novel assay that directly quantifies endogenous DGAT activity through the use of a fluorescently labeled substrate. We performed this assay with microsomal protein, 2-(6-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)hexanoyl-1-hexadecanoyl-sn-glycero-3-diacylglycerol (NBD-DAG), and oleoyl-CoA substrates. DGAT activity was analyzed in three species of algae as well as rat liver. The protocol proved to be sensitive and reliable. This assay may be used to facilitate research in the areas of biodiesel, oilseed crops, and triacylglycerol-related human pathologies.

These results suggest that although the survival of these implanted grafts is reduced, it is secondary to extra-hepatic factors. Disclosures: The following people C646 mouse have nothing to disclose: Francis P. Robertson, Pulathis Siri-wardana, Paul R. Bessell, Rafael Diaz-Nieto, Nancy Rolando, Brian R. Davidson Background: Portal vein thrombosis (PVT) occurs in 3-7% of adult patients following orthotopic liver transplantation (OLT). The long term consequences and potential impact on graft and patient survival remain unknown. Methods: We identified seventeen

patients who underwent a liver transplant at our institution between January 2006 and December 2013 and developed PVT following OLT (PVT group) and compared their outcomes to those of 51 controls who had received a liver transplant during the same time period selleck products (non-PVT group). Controls were matched to cases on the basis of age, gender, body mass index (BMI) and etiology of liver disease. Graft survival was defined as time from transplantation to death, last follow-up or re-transplantation. Kaplan Meier survival analysis was used to compare graft and patient survival between both groups. Results: Baseline patient and donor characteristics were similar between both groups. There was no statistically significant difference in the incidence of biopsy proven acute or chronic rejection and biliary complications (anastomotic

and non-anastomotic strictures) between both groups. Seven 上海皓元医药股份有限公司 patients (41%) in the PVT group had esophageal and/or gastric varices detected endoscopically or on imaging, compared to 7/51 (14%) of patients in the control group (p=0.016). Variceal bleeding occurred in 12% of patients in the PVT group compared to 4% of patients in the control group (p=0.06). Clinically significant ascites occurred in 9/17 patients in the PVT group (53%) compared to 10/41 patients in the control group (19.6%) (p=0.0085). Overt hepatic encephalopathy occurred in 2/17 patients

in the PVT group (12%) compared to 1/51 (2%) of patients in the control group (p=0.09). Interestingly, patients in the PVT group were also more likely to develop hepatic artery thrombosis (HAT) compared to patients in the control group (23.5% vs 5.9% respectively; p= 0.04). Seven patients in the PVT group (41%) died compared to 11 in the control group (21%) (p=0.11). The main cause of death in both groups was sepsis, followed by cardiovascular disease and malignancy. There was no statistically significant difference in graft and patient survival between both groups. Mean duration of follow up was 976±707 days for the PVT group and 1187±728 days for the control group (p=0.3). Conclusion: New PVT following OLT did not impact graft or patient survival, however patients with PVT post transplantation were more likely to develop varices and clinically significant asci-tes. Variceal bleeding and hepatic encephalopathy occurred more frequently amongst PVT patients but the difference did not reach statistical significance.